FTC Wants To Extend Actavis To Authorized Generics Deals

Law360, New York (August 16, 2013, 7:05 PM ET) -- The Federal Trade Commission on Wednesday urged a New Jersey federal judge overseeing private antitrust litigation targeting an authorized generics deal between Wyeth LLC and Teva Pharmaceuticals USA Inc. to apply the U.S. Supreme Court's recent pay-for-delay ruling to the case.

The FTC sought permission to file an amicus curiae brief arguing that a promise by a branded drugmaker not to launch its own authorized generic version of a drug during a generics company's exclusivity period functioned the same way that straight payments to generic-drug makers...
To view the full article, register now.